Evidence map›Paper›PMID 42337606›Full record

ArticleJournal of nanobiotechnology2026

PD-L1-targeted OMV priming licenses myeloid co-stimulation and chemokine circuits to potentiate CAR-T therapy in advanced-stage solid tumors.

Yueyao Yang, Junjie Peng, Jing Wei, Jia Qin, Yang Jiao, Ming Liu, Gang Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yueyao YangNational Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, 610064, Sichuan Province, China.
Junjie PengNational Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, 610064, Sichuan Province, China.
Jing WeiDepartment of Medical Oncology, Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.
Jia QinNational Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, 610064, Sichuan Province, China.
Yang JiaoNational Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, 610064, Sichuan Province, China.
Ming LiuDepartment of Medical Oncology, Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, China.
Gang WangNational Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, 610064, Sichuan Province, China. wgang@scu.edu.cn.ORCID https://orcid.org/0000-0003-3296-3015

Funding

International Science and Technology Innovation Cooperation Project of Sichuan Province 2025YFH0142Key Project of Sichuan Provincial Administration of Traditional Chinese Medicine 2024zd031Sichuan Provincial Science and Technology Support Program 2023YFS0111
6 · The paper itself

Abstract

backgroundChimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in hematologic malignancies, yet its efficacy in solid tumors is frequently limited by an immunosuppressive tumor microenvironment (TME) that restrains trafficking, persistence, and effector function. Targeted priming strategies that remodel myeloid compartments and reinforce intratumoral co-stimulation may help overcome these barriers.

methodsWe engineered bacterial outer membrane vesicles displaying PD-L1-targeting single-chain variable fragment (OMV

resultsOMV

conclusionsPD-L1-directed OMV priming provides a modular, systemic strategy to reprogram the solid-tumor immune ecosystem by licensing myeloid compartments and reinforcing intratumoral co-stimulation, thereby supporting improved CAR-T recruitment and function. These findings establish engineered OMVs as a mechanistically grounded priming platform to complement CAR design for solid tumor immunotherapy.

Indexed as

B7-H1 AntigenChemokinesImmunotherapy, AdoptiveNeoplasmsSingle-Chain AntibodiesAnimalsCell Line, TumorDendritic CellsFemaleHumansMacrophagesMiceMyeloid CellsTumor MicroenvironmentB7-H1 AntigenChemokinesSingle-Chain AntibodiesBacterial outer membrane vesiclesCAR-TCo-stimulationDendritic cellsMacrophage reprogrammingPD-L1Single-cell RNA sequencingTtumor microenvironment

Identifiers

PMID42337606
PMCPMC13543469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.